Loading organizations...
§ Private Profile · Cambridge, MA, USA
Orna Therapeutics is a technology company.
Orna Therapeutics develops fully engineered circular RNA (oRNA) therapeutics, representing a novel class of RNA medicines. The company leverages its proprietary oRNA and lipid nanoparticle (LNP) platform technologies to design therapies. This approach focuses on RNA constructs with enhanced stability and improved protein expression over linear RNA, aiming for potent, durable therapeutic effects across various therapeutic areas.
Co-founded in 2021 by Ansbert Gadicke, M.D., who also serves as Chairman of the Board and is a Managing Partner at MPM BioImpact, Orna Therapeutics originated from a key scientific insight. The founders identified circular RNA's inherent advantages, particularly its stability and sustained protein production, over conventional linear RNA, propelling the company's formation to realize its therapeutic promise.
Orna Therapeutics' products are intended for patients in diverse disease areas, including oncology and autoimmune conditions. The company's vision is to establish circular RNA as a foundational new modality in medicine. By continually advancing its oRNA platform, Orna aims to deliver transformative therapeutic solutions, addressing significant unmet medical needs.
Orna Therapeutics has raised $320.0M across 3 funding rounds.
Orna Therapeutics has raised $320.0M in total across 3 funding rounds.
Orna Therapeutics is a biotechnology company developing fully engineered circular RNA (oRNA) therapeutics, a new class of RNA medicines designed to outperform traditional linear mRNA in protein expression, production simplicity, and delivery.[1][2][6] It builds oRNA platforms combined with proprietary lipid nanoparticle (LNP) delivery systems like panCAR™ for in vivo CAR therapies and STEM™ for bone marrow targeting, serving patients with oncology, autoimmune diseases, infectious diseases, and genetic disorders such as sickle cell disease and beta-thalassemia.[2][3][5] Orna solves key limitations of existing therapies—including ex vivo cell engineering's preconditioning needs, linear mRNA's immunogenicity and instability, and liver-only delivery—by enabling off-the-shelf, redosable treatments that generate multiple immune cell types in vivo with higher efficacy and lower risk.[2][3][4][5] The company shows strong growth momentum through an $80M+ Series A in 2021, a 2022 Merck collaboration on vaccines, and an advancing pipeline targeting IND filings by 2026.[3][4][6]
Founded in 2019 in Cambridge, Massachusetts, Orna Therapeutics emerged from groundbreaking MIT research on synthetic circular RNA, initially backed by MPM Capital with over $100M raised at launch in February 2021 via an $80M Series A.[1][6] The idea stemmed from nature-inspired rational design to overcome linear mRNA's flaws, like degradation and immune activation, by creating self-circularizing oRNA for superior stability and expression.[2][5][6] Key founders and leaders bring deep expertise: the team includes veterans in oRNA/LNP development, drug programs like the approved BEQVEZ for hemophilia B, and spin-outs like Cerevel Therapeutics from Pfizer.[7] Early traction came from platform validation in preclinical data for panCAR™ in autoimmune and oncology, plus the Merck partnership in 2022, positioning Orna as a leader in RNA innovation.[2][3][4]
Orna stands out through its integrated oRNA and LNP platforms, delivering advantages over linear mRNA and cell therapies:
Orna rides the RNA therapeutics revolution post-mRNA vaccines, extending it beyond liver targets and infectious diseases into oncology, autoimmunity, and genetics via circular RNA's durability and novel LNPs.[2][5] Timing is ideal amid surging demand for in vivo CAR therapies—avoiding ex vivo manufacturing bottlenecks—and rising focus on scalable, patient-friendly alternatives to viral vectors or preconditioned cell therapies.[3][4] Market forces like Merck's validation, preclinical successes, and RNA's cost-effective scalability favor Orna, influencing the ecosystem by redefining RNA as a versatile, "fully engineered" modality that could disrupt $100B+ immunotherapy and gene-editing markets.[2][6] It accelerates "off-the-shelf" innovation, lowering barriers for hard-to-treat indications and inspiring hybrid RNA platforms.[1][5]
Orna is poised for clinical breakthroughs, with panCAR™ INDs targeted by 2026, Merck milestones, and expansion into genetic diseases via STEM™.[3] Trends like AI-optimized RNA design, non-liver LNPs, and in vivo immune engineering will propel it, potentially yielding first approvals in autoimmune/oncology by late 2020s. Its influence may evolve from platform pioneer to multi-product leader, reshaping RNA meds as the go-to for systemic diseases—unlocking the "limitless potential" of oRNA to transform patient care beyond linear limits.[2]
Orna Therapeutics has raised $320.0M in total across 3 funding rounds.
Orna Therapeutics's investors include BioImpact Capital, Abingworth, ARCH Venture Partners, MPM Capital, Morana Jovan-Embiricos, Atlas Venture, Hakan Goker, Seroba Life Sciences, Taiho Ventures, Astellas Venture Management, Bristol Myers Squibb, Francesco Marincola.
Orna Therapeutics has raised $320.0M across 3 funding rounds. Most recently, it raised $220.0M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2022 | $220M Series B | Bioimpact Capital | Abingworth, ARCH Venture Partners, MPM Capital | Announced |
| Feb 1, 2021 | $80M Series A | MPM Capital, Morana Jovan Embiricos | Abingworth, ARCH Venture Partners, Atlas Venture, Hakan Goker, Seroba Life Sciences, Taiho Ventures, Astellas Venture Management, Bristol Myers Squibb, Francesco Marincola, Novartis Institutes For Biomedical Research, Pagsgroup | Announced |
| Dec 1, 2019 | $20M Seed | — | Abingworth, ARCH Venture Partners, Atlas Venture, MPM Capital | Announced |